Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681125 | 0.86 | IP6K1 (0.48) | IP6K1KDM4EGLAGAACRBN | |
| SCHEMBL30681127 | 0.83 | PSEN1 (0.41) | IP6K1CRBNBACE1 | |
| SCHEMBL30681143 | 0.76 | IP6K1 (0.43) | IP6K1KDM4EGLAGAABACE1 | |
| SCHEMBL22711811 | 0.73 | IP6K1 (0.56) | IP6K1CRBNMEN1KMT2A | |
| SCHEMBL22711631 | 0.72 | IP6K1 (0.44) | IP6K1CRBNBACE1PARP1 | |
| SCHEMBL31414299 | 0.71 | PGR (0.40) | IP6K1MEN1KMT2A | |
| SCHEMBL29621928 | 0.68 | PGR (0.40) | IP6K1MEN1KMT2ABACE1 | |
| SCHEMBL522062 | 0.68 | CA12 (0.52) | KDM4EGLAGAAPOLBABL1 | |
| SCHEMBL23778287 | 0.67 | MEN1 (0.42) | BRD4MEN1POLBKMT2ABACE1 | |
| SCHEMBL4398639 | 0.67 | GAA (0.37) | KDM4EGLAGAAPOLBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346572-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | LIEBER INST INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4539838-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Lieber Institute, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244657-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346572-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | IP6K1, IP6K2, IP6K3 | IP6K1 1/4885KDM4E 3177/4885GLA 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.